Envol Biomedical
Envol Biomedical is a private US preclinical contract research organization providing non-human primate-based pharmacology, pharmacokinetics, toxicology, imaging, surgical, and bioanalytical services to pharmaceutical and biotech sponsors, operating the largest NHP supply in North America from a 75,000+ sq ft facility.
- Company typePrivate
- Founded2019
- HeadquartersNew City, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Envol Biomedical does
Envol Biomedical is a private, US-based preclinical contract research organization founded in 2019, headquartered in New City. The company specializes in non-human primate (NHP) research services for pharmaceutical and biotech sponsors developing small molecules, biologics, and gene therapies, and positions itself as the largest provider of NHP subjects in North America. Operations run from a 75,000+ square foot AAALAC-accredited, USDA-registered, and OLAW-compliant facility with GLP compliance, vertically integrating breeding and colony management with downstream study execution.
The company's product platform spans pharmacology services, pharmacokinetics (PK), GLP and non-GLP toxicology, core laboratory and bioanalytical services, imaging, and surgical capabilities including MRI-guided neurosurgery delivered through a partnership with ClearPoint Neuro. Specialized therapeutic area coverage includes obesity and metabolic disease, gene therapy, CNS, respiratory, and ocular indications. An AI-enabled toxicology reporting platform was launched in 2024 for real-time data transformation, and the company participates in the LNP Alliance with NeoSome Life Sciences, NIS Nanoimaging Services, and Phosphorex for lipid nanoparticle and gene therapy research. Other operational partners include ODIN Bioscience (biological matrices), TOXPLUS (GLP monitoring), Resero (PK modeling), and Endpoint Preclinical.
Envol operates a professional services, quote-based revenue model with multi-year enterprise contracts. Go-to-market relies on direct enterprise field sales targeting pharma and biotech decision-makers and study directors, supplemented by active presence at major industry conferences (SOT, BIO, ACT, ASGCT), scientific publications and thought leadership, and webinars with partners. The leadership team includes veterans of Lovelace Biomedical, Charles River Laboratories, Biomere, SNBL USA, and academic institutions including Johns Hopkins, Stanford, and NIH. The company is founder/management-led with no disclosed institutional investment or funding rounds.
Envol Biomedical firmographics
Firmographics- Name
- Envol Biomedical
- Legal name
- Envol Biomedical
- Website
- https://envolbio.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Envol Biomedical is a private US preclinical contract research organization providing non-human primate-based pharmacology, pharmacokinetics, toxicology, imaging, surgical, and bioanalytical services to pharmaceutical and biotech sponsors, operating the largest NHP supply in North America from a 75,000+ sq ft facility.
- Ownership category
- akta.pro rank
Envol Biomedical industry classification
Industry- Product category
- Preclinical Contract Research Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Electronic Data Capture (EDC) Platforms (HLACAOAA)
Keywords
Where Envol Biomedical is headquartered
LocationHeadquarters
- HQ city
- New City
- HQ country
- United States
- HQ region
- North America
Markets served
Envol Biomedical business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Preclinical Contract Research Services: Contract research services encompassing pharmacology, pharmacokinetics, toxicology, imaging, and surgical services for pharmaceutical and biotech companies developing therapeutics.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom contract research pricing based on study scope and requirements |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
Envol Biomedical product offering
Product offeringCore offering
Envol Biomedical is a preclinical contract research organization that provides non-human primate (NHP)-based pharmacology, pharmacokinetics, toxicology, surgical, imaging, core laboratory, and biological matrices services for pharmaceutical and biotech sponsors. The company also operates an AAALAC-accredited NHP breeding and colony management program, making it the largest provider of NHP subjects in North America, and delivers integrated GLP-compliant study execution from discovery through IND-enabling development.
Product overview
Envol Biomedical operates as a preclinical contract research organization (CRO) offering an integrated platform of services for drug development. The core offering includes Pharmacology Services, Pharmacokinetics (PK) Services with Resero integration, Toxicology Services with AI-enabled reporting and TOXPLUS GLP monitoring, Core Laboratory Services with biological matrix capabilities, and Imaging Services including MRI-guided neurosurgical capabilities via ClearPoint Neuro. The company provides Breeding & Colony Management services and extends its offerings through the LNP Alliance Partnership program with NeoSome Life Sciences, NIS Nanoimaging Services, and Phosphorex. All services maintain GLP compliance with SEND compatibility for regulatory submissions.
Differentiator
Problem solved
Functional benefit
Products and services
- Pharmacology Services Translational pharmacology studies in non-human primate (NHP) models, including efficacy testing, dose-response, and mechanism of action investigations for drug development programs. Designed for pharmaceutical and biotech sponsors advancing small molecules, biologics, and gene therapies.
- Pharmacokinetics (PK) Services Advanced pharmacokinetic studies in NHPs delivering ADME (absorption, distribution, metabolism, and excretion) profiling, with PK modeling and reporting supported by Resero integration. Targeted at pharmaceutical and biotech sponsors needing IND-enabling PK data.
- Toxicology Services GLP-compliant toxicology programs in NHPs, including acute, subchronic, and chronic toxicity assessments, with AI-enabled reporting and TOXPLUS-powered monitoring. Built to accelerate IND readiness for pharmaceutical and biotech sponsors.
- Core Laboratory Services Comprehensive analytical, bioanalytical, and molecular assay support including sample analysis, biomarker quantification, and biological matrix analysis through ODIN Bioscience integration. Provides the data backbone for pharmacology, PK, and toxicology studies.
- Imaging Services Advanced imaging capabilities integrated across preclinical programs, including MRI-guided neurosurgical procedures through the ClearPoint Neuro partnership. Supports surgical precision, disease modeling, and data interpretation in NHP studies.
- Surgical Capabilities In-house surgical team enabling complex dosing, serial sampling, and targeted delivery in NHP studies with clinical-grade precision and cross-functional coordination. Includes MRI-guided neurosurgery via ClearPoint Neuro.
- Breeding & Colony Management AAALAC-accredited, USDA-registered, OLAW-compliant in-house breeding and colony management programs ensuring animal health, genetic integrity, and regulatory compliance. Provides consistent, study-ready NHP models for pharmacology, toxicology, and surgical research.
- Biological Matrices High-quality biological matrices including blood, tissues, cells, and biofluids sourced through ODIN Bioscience and integrated into GLP laboratory workflows for reliable, reproducible research outcomes.
Quantifiable outcome
- Largest NHP subject provider in North America
Companies that use Envol Biomedical
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Envol Biomedical technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability4 records
Feature3 records
Envol Biomedical partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and supporting.
- ODIN BiosciencecoreStrategic partnership providing biological matrices for preclinical research studies, supporting Envol's comprehensive service offerings in toxicology and pharmacokinetics.
- LNP AlliancecoreEnvol serves as the expert NHP partner within the LNP Alliance, collaborating with NeoSome Life Sciences, NIS Nanoimaging Services, and Phosphorex to provide integrated solutions for lipid nanoparticle and gene therapy research.
- TOXPLUScoreCollaboration for GLP study monitoring services, combining Envol's NHP research capabilities with TOXPLUS's toxicology expertise for comprehensive preclinical safety assessment.
- ReserosupportingPartnership for pharmacokinetic modeling and reporting services, integrating Envol's study execution with Resero's analytical and modeling capabilities.
- ClearPoint NeurocoreCollaboration providing MRI-guided neurosurgical capabilities for complex CNS and gene therapy preclinical studies, enabling precise delivery and assessment of therapeutic candidates.
- Endpoint PreclinicalsupportingPartnership to expand capabilities and provide comprehensive preclinical solutions, leveraging complementary expertise and infrastructure.
- White Oak Regulatory ToxsupportingJoint marketing and presentation partnership at ACT 2025 conference, showcasing combined regulatory toxicology expertise to prospective clients.
- NeoSome Life SciencescoreMember of LNP Alliance, collaborating on lipid nanoparticle research with Envol providing NHP expertise.
- NIS Nanoimaging ServicescoreMember of LNP Alliance, providing nanoimaging capabilities for nanoparticle and gene therapy biodistribution studies.
- PhosphorexcoreMember of LNP Alliance, contributing formulation and delivery expertise for nanoparticle-based therapeutics research.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Envol Biomedical competitors and assessment
Company assessmentDirect peers
- Lovelace Biomedical Research Institute: Preclinical CRO where Envol's CEO Jake McDonald was previously CSO/VP. Competes in the same NHP toxicology and inhalation pharmacology space with similar therapeutic area coverage.
- SNBL USA: NHP-specialized preclinical CRO with primate breeding and toxicology capabilities. Envol's attending veterinarian formerly directed SNBL USA's primate facility, making SNBL one of the closest direct comparables in NHP-focused preclinical services.
- Sinclair Research: NHP-focused preclinical CRO offering toxicology, pharmacology, and surgical services. Envol's co-founder Alain Stricker-Krongrad previously held a C-suite role at Sinclair, and the two compete for the same NHP IND-enabling study budget.
- Biomere: Preclinical CRO specializing in NHP and rodent toxicology/pharmacology. Another former employer of Envol's co-founder, Biomere is a direct competitor for NHP safety assessment and efficacy studies.
Broad incumbents
- WuXi AppTec: Global CRO with large preclinical and biologics capacity. Competes for outsourced pharma R&D programs, though geopolitical scrutiny of WuXi has redirected some U.S. sponsor work toward domestic NHP providers like Envol.
- Labcorp Drug Development (Covance): Global CRO offering integrated preclinical and clinical services. Competes with Envol for multi-modality pharma outsourcing programs where sponsors prefer bundled providers.
- IQVIA: Largest clinical CRO with preclinical capabilities. Represents an entrenched competitor for large pharma outsourcing relationships, particularly where clients value end-to-end preclinical-to-Phase IV coverage.
- MPI Research (now part of Charles River): Preclinical CRO specializing in safety assessment, including NHP studies. Now integrated into Charles River, it competes with Envol for IND-enabling toxicology work; Envol's Technical Operations Manager previously worked at MPI.
- Charles River Laboratories: Largest NHP and broader preclinical CRO globally. Envol's co-founder previously held a C-suite role here, and Charles River remains the dominant incumbent Envol directly competes against for large pharma preclinical programs.
Emerging players
- Pacific BioLabs: Mid-sized preclinical CRO providing GLP toxicology, pharmacology, and analytical services to pharma and biotech. Comparable in scale to Envol with overlapping capabilities in regulatory-grade preclinical studies.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Envol Biomedical compliance and trust
Trust signalCompliance4 records
Envol Biomedical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Envol Biomedical leadership team
Management profileNumber of profiles
Profiles11 records
Envol Biomedical funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Envol Biomedical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Envol Biomedical
What does Envol Biomedical do?
Envol Biomedical is a preclinical contract research organization that provides non-human primate (NHP)-based pharmacology, pharmacokinetics, toxicology, surgical, imaging, core laboratory, and biological matrices services for pharmaceutical and biotech sponsors. The company also operates an AAALAC-accredited NHP breeding and colony management program, making it the largest provider of NHP subjects in North America, and delivers integrated GLP-compliant study execution from discovery through IND-enabling development.
Is Envol Biomedical a public or private company?
Envol Biomedical is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Envol Biomedical founded?
Envol Biomedical was founded in 2019. It employs 51 to 100 people.
Where is Envol Biomedical based?
Envol Biomedical is headquartered in New City, United States, in the North America region.
How does Envol Biomedical make money?
One revenue line is on record: preclinical Contract Research Services.
Who are Envol Biomedical's main competitors?
Direct peers on record are Lovelace Biomedical Research Institute, SNBL USA, Sinclair Research and Biomere. Broad incumbents are WuXi AppTec, Labcorp Drug Development (Covance), IQVIA, MPI Research (now part of Charles River) and Charles River Laboratories. Pacific BioLabs is listed as an emerging player.
Does Envol Biomedical have an API?
No public API is recorded for Envol Biomedical.
What industry is Envol Biomedical in?
Envol Biomedical's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLACAOAA, Electronic Data Capture (EDC) Platforms. Its NAICS code is 541714 and its SIC code is 8731.